001390481 000__ 02610cam\\2200553\i\4500
001390481 001__ 1390481
001390481 003__ OCoLC
001390481 005__ 20220420003056.0
001390481 007__ he\bmb024bbca
001390481 008__ 220415s2020\\\\dcu\\\\\b\\\\f000\0\eng\c
001390481 035__ $$a(OCoLC)1311088414
001390481 040__ $$aGPO$$beng$$erda$$cGPO$$dGPO$$dISE
001390481 042__ $$apcc
001390481 043__ $$an-us---
001390481 049__ $$aISEA
001390481 074__ $$a1043-B (MF)
001390481 0860_ $$aY 4.L 11/4:S.HRG.115-788
001390481 1101_ $$aUnited States.$$bCongress.$$bSenate.$$bCommittee on Health, Education, Labor, and Pensions,$$eauthor.
001390481 24010 $$aOpioid crisis (2018 March 8)
001390481 24514 $$aThe opioid crisis :$$bleadership and innovation in the states : hearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Fifteenth Congress, second session, on examining the opioid crisis, focusing on leadership and innovation in the states, March  8, 2018.
001390481 2463_ $$aExamining the opioid crisis, focusing on leadership and innovation in the states
001390481 264_1 $$aWashington :$$bU.S. Government Publishing Office,$$c2020.
001390481 300__ $$aiii, 40 pages ;$$c24 cm.
001390481 336__ $$atext$$btxt$$2rdacontent
001390481 337__ $$amicroform$$bh$$2rdamedia
001390481 338__ $$amicrofiche$$bhe$$2rdacarrier
001390481 4901_ $$aS. hrg. ;$$v115-788
001390481 500__ $$aShipping list no.: 2021-0115-M.
001390481 5110_ $$aHearing witnesses: Statement of Hogan, Hon. Lawrence J., Governor, Sate of Maryland; Statement of Brown, Hon. Kate, Governor, State of Oregon.
001390481 518__ $$aDate of hearing: 2018-03-08.
001390481 533__ $$aMicrofiche.$$b[Washington, D.C.] :$$cU.S. Government Printing Office,$$d[2020]$$e1 microfiche : negative.
001390481 650_0 $$aOpioid abuse$$zUnited States$$xPrevention$$xStates.
001390481 650_0 $$aOpioid abuse$$xTreatment$$zUnited States.
001390481 650_0 $$aDrug utilization$$zUnited States$$xData processing.
001390481 650_0 $$aDrug abuse$$zUnited States$$xPrevention$$xFinance.
001390481 650_6 $$aToxicomanie aux opiacés$$0(CaQQLa)201-0338718$$xTraitement$$0(CaQQLa)201-0377521$$zÉtats-Unis.$$0(CaQQLa)201-0407727
001390481 650_6 $$aMédicaments$$0(CaQQLa)201-0011172$$xUsage$$0(CaQQLa)201-0011172$$zÉtats-Unis$$0(CaQQLa)201-0407727$$xInformatique.$$0(CaQQLa)201-0380011
001390481 650_6 $$aToxicomanie$$0(CaQQLa)201-0168521$$zÉtats-Unis$$0(CaQQLa)201-0407727$$xPrévention$$0(CaQQLa)201-0168521$$xFinances.$$0(CaQQLa)201-0168521
001390481 650_7 $$aDrug abuse$$xPrevention$$xFinance.$$2fast$$0(OCoLC)fst00898526
001390481 650_7 $$aOpioid abuse$$xTreatment.$$2fast$$0(OCoLC)fst01430931
001390481 651_7 $$aUnited States.$$2fast$$0(OCoLC)fst01204155
001390481 655_7 $$aLegislative hearings.$$2fast$$0(OCoLC)fst01910825
001390481 655_7 $$aLegislative hearings.$$2lcgft
001390481 655_7 $$aAudiences législatives.$$2rvmgf$$0(CaQQLa)RVMGF-000001453
001390481 8101_ $$aUnited States.$$bCongress.$$bSenate.$$tS. hrg. ;$$v115-788.
001390481 852__ $$bedoc$$hY 4.L 11/4:S.HRG.115-788
001390481 852__ $$bdfich
001390481 85640 $$uhttps://purl.fdlp.gov/GPO/gpo137251
001390481 909CO $$ooai:library.usi.edu:1390481$$pGLOBAL_SET
001390481 980__ $$aBIB
001390481 980__ $$aEGOV
001390481 982__ $$aGovernment E-Resource
001390481 983__ $$aOnline
001390481 994__ $$aC0$$bISE